Trial Profile
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 May 2020 Results (n=135) assessing changes from baseline in migraine-specific patient-reported outcomes (PRO) measures of patient functioning and disability in patients with migraine, presented at the 72nd Annual Meeting of the American Academy of Neurology.
- 27 Apr 2020 Results to characterize the immunogenicity profile of galcanezumab across four phase 3 clinical trials (Evolve-1, Evolve-2, Regain, NCT01625988, NCT02163993 and NCT02614287) and CGAJ (NCT02614287) in which patients with episodic or chronic migraine were treated for up to 52 weeks published in the Cephalalgia
- 12 Dec 2018 Status changed from active, no longer recruiting to completed.